Chelsea Nimmo practises in all areas of intellectual property law, with a focus on pharmaceutical patent litigation. Ms. Nimmo joined the Toronto office as a summer student in 2013 and articled with us in 2014-2015. During her articles, Ms. Nimmo was seconded to GlaxoSmithKline Inc. where she gained valuable experience working on commercial and regulatory matters.
During law school, Ms. Nimmo was a managing editor for the McGill Journal of Law and Health. She also went on an international exchange to the National University of Singapore, where she focused her studies on biotechnology law.
Prior to law school, Ms. Nimmo completed a master’s degree in chemistry. Her graduate research focused on the synthesis of biomaterials for tissue engineering applications. Ms. Nimmo’s research has been published in peer-reviewed scientific journals.
B.C.L./LL.B, McGill University, 2014
M.Sc., Chemistry, University of Toronto, 2011
B.Sc., Biochemistry, McGill University, 2009
Memberships and activities
- Canadian Bar Association
- Intellectual Property Institute of Canada
- Law Society of Upper Canada
- Ontario Bar Association
- The Advocates’ Society
- Toronto Intellectual Property Group
The Canadian Senate has passed Bill C-30 (the act intended to implement CETA), the final major stage of the legislative process. Bill C-30 will become law once it receives royal assent, which we expect to happen shortly..
May 12, 2017
Major reforms to Canada’s Patent Act are coming soon, including the implementation of patent term restoration (i.e., Certificates of Supplementary Protection (CSP)), which may extend the patent term of eligible pharmaceutical products by up to two years..
May 04, 2017